Jupiter Neurosciences, Inc. (NASDAQ: JUNS) completed a registered direct offering of 7,142,858 shares of common stock, generating approximately $2 million in gross proceeds. The clinical-stage biopharmaceutical company focuses on central nervous system disorders and neuroinflammation.

D. Boral Capital LLC served as the exclusive placement agent for the offering. The shares were sold under an effective shelf registration statement on Form S-3, which the Securities and Exchange Commission declared effective on April 24, 2026.

Jupiter's lead program, JOTROL, is a proprietary resveratrol formulation currently in a Phase IIa clinical trial for Parkinson's disease. The company also markets Nugevia, a consumer longevity supplement, and recently acquired U.S. rights to ALA-002, described as a next-generation psychedelic compound.

The offering was conducted pursuant to a prospectus supplement filed with the SEC. D. Boral Capital, headquartered in New York, states it has aggregated approximately $35 billion in capital since its 2020 inception through roughly 400 transactions. The firm is a member of FINRA and SIPC.

Information about the offering is based on the company's press release statement.